BACK BY POPULAR DEMAND-! GBA'S GENRAL STORE OF STOCKS.
This is a Stock Newsletter that contains only stocks you do not know, have never heard of and are being kept from you. It is a free form Interview with GBA's Co-Head Of Investing Stoned Investor. This Interview is being held in rainy Ct where it has rained for ten days straight.
Q: Hello SI we understand you live very close to a stream or brook, how are you holding up?
SI: The water is raging & turbulent and so is the stock market.
Q: Give us The Big View if you would.
<<<THE BIG VIEW>>>
View Inc. smart windows selected for renovation of 100 Pearl Street. Pearl street is not as fish smelly as it used to be that's high end real estate now.
(VIEW) View announced its smart windows will be installed at the new overbuild at 100 Pearl Street, a Class-A office tower in Lower Manhattan currently undergoing a top-to-bottom transformation by GFP Real Estate and Northwind Group. 100 Pearl Street is being renovated into a downtown New York City office asset with all-glass penthouses offering 360-degree views across the East River toward Brooklyn and south over New York Harbor to the Statue of Liberty. The design of the double-height, 24-foot all-glass penthouses are made possible by View Smart Windows.
I've been looking for another DIRTT... & VIEW may be it---
WalkMe initiated with an Overweight at Morgan Stanley (WKME) Morgan Stanley analyst Josh Baer initiated coverage of WalkMe with an Overweight rating and $41 price target. He thinks the value of WalkMe's differentiated capabilities are underappreciated and expects WalkMe will be able to maintain its leading position as its intuitive, guided experiences can optimize users' interactions with software, Baer tells investors. Increasing sales capacity, focusing on partnership and building out a WalkMe ecosystem, moving up-market and expanding internationally can all drive accelerating Annual Recurring Revenue growth for WalkMe, Baer contends.
WalkMe initiated with an Overweight at Wells Fargo (WKME) Wells Fargo analyst Michael Turrin initiated coverage of WalkMe with an Overweight rating and $40 price target. The company is pioneering a new category of software known as the digital adoption platform, Turrin tells investors in a research note. The company saw "impressive" pre-pandemic growth and it poised for a rebound post a shift back into investment mode and a more favorable hybrid work environment to sell into, Turrin tells investors in a research note.
BAD IDEA DEPT.**
Amazon approved to use airwaves for sleep monitoring, Bloomberg reports AMZN
GREEK FREAK WINS! & is upgraded (again)
Outokumpu upgraded to Outperform from Neutral at Oddo BHF 06:17 OUTKY Oddo BHF analyst Alain William upgraded Outokumpu to Outperform from Neutral with a EUR 7 price target.
Just finished Halston on Netflix. It is so so. Gets very depressing. I lived those days!
Coty to introduce digitally-enabled touch-less fragrance testing device 06:14 COTY - That seems smart the job of spraying you when you walk in a department Store... Covid may have killed that job off entirely... AND THIS WAS HOW YOU BOUGHT PERFUME IN THE OLD DAYS.
**Biohaven Pharmaceutical price target
raised to $134 from $92 at Mizuho 06:39
BHVN
Electric Last Mile Solutions signs long-term supply agreement with Wuling Motors 07:03 ELMS
Bio Idea*
Verve Therapeutics initiated with a Buy at Guggenheim 07:01 VERV Guggenheim analyst Etzer Darout initiated coverage of Verve Therapeutics with a Buy rating and
$84 price target.
Verve Therapeutics initiated with an Outperform at William Blair 07:00 VERV William Blair analyst Raju Prasad initiated coverage of Verve Therapeutics with an Outperform rating
and $92 fair value estimate. Verve is developing one-time medicines for the treatment of cardiovascular diseases that have the potential to disrupt the current chronic care model, Prasad tells investors in a research note. The analyst says the company has generated "compelling"
preclinical data in nonhuman primates with over 60% whole liver editing resulting in near-complete reductions in serum PCSK9 or ANGPTL3 protein levels and "impressive" lowering of LDL-C and triglycerides.
Q- How bout a yield idea?
TriplePoint Venture initiated with an Overweight at Piper Sandler 06:07 TPVG Piper Sandler analyst Crispin Love initiated coverage of TriplePoint Venture Growth with an Overweight rating and $17 price target. The company's "attractive" technology focused portfolio and record venture capital activity should drive debt demand,
its nearly 10% distribution yield and its valuation, Love tells investors in a research note. The analyst believes TriplePoint should trade a premium to business development company peers due to the "strong" venture capital activity, which he says "provides a long runway for venture debt funding."
Q- Alright thank you sir... Any last quickies?
Tutor Perini unit awarded
$220M design-build contract 06:05
TPC
NewAge forms manufacturing partnership with TCI Co. 06:04
NBEV
Citi opens '90-day positive Catalyst Watch' on Network International 05:49
NWITY
AST SpaceMobile initiated with an Overweight at Barclays 05:31 ASTS Barclays analyst Mathieu Robilliard initiated coverage of AST SpaceMobile with an Overweight rating and $29 price target The company's "proposition is unique and the addressable market is very significant," with its goal of extending mobile coverage everywhere via satellite, Robilliard tells investors in a research note. This promises to address a growing policy priority for governments: bridging the digital divide, says the analyst. Robilliard says that if the technology works as planned and management executes, he sees a "compelling investment opportunity."
Q- Wow that's about 12 names to research today! Is there any parting comment you want to leave our audience with?
SI- Always close your sunroof in times of heavy rain.